Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
09 janv. 2023 07h00 HE | Tenaya Therapeutics, Inc.
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301...
1672867636549blob.jpg
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
05 janv. 2023 07h50 HE | Curative Biotechnology, Inc. 
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments...
logo.png
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
28 déc. 2022 07h00 HE | BIOXYTRAN, INC.
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...
ehave-logo.png
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
15 déc. 2022 08h00 HE | Ehave
MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today...
SparingVision logo avec baseline HD.jpg
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
01 déc. 2022 07h00 HE | SparingVision
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa SparingVision set to advance into the clinic with breakthrough gene-independent approach...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
16 nov. 2022 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
NKGen Biotech RGB small.jpg
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE | NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
Atyr_Logo.png
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
29 sept. 2022 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
16 août 2022 14h53 HE | The Rosen Law Firm PA
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302
06 juil. 2022 09h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...